Literature DB >> 30006661

[Importance of phototherapy in the treatment of chronic pruritus].

Franz J Legat1.   

Abstract

Phototherapy and photochemotherapy (PUVA) are important treatment modalities in inflammatory skin diseases such as psoriasis and atopic dermatitis as well as in cutaneous T‑cell lymphoma (e.g., mycosis fungoides/Sezary syndrome). Many of these skin diseases are accompanied by distracting pruritus. In addition, patients may suffer from intense pruritus in systemic diseases of the kidney and liver as well as of the endocrine and hematopoietic system. UV-light during phototherapy is capable of not only improving the inflammatory skin lesions but also of reducing the pruritus in skin and systemic diseases. The significant antipruritic effect, the usually low rate of well-known side effects, as well as the possibility to treat adults of any age, pregnant and lactating women, and under certain circumstances also children, make phototherapy a valuable treatment option for pruritus of various origin. Thus, the use of phototherapy should be considered early in the course of antipruritic therapy, when topical treatment modalities are insufficient to significantly improve pruritus.

Entities:  

Keywords:  Chronic prurigo; Inflammatory skin diseases; PUVA; Systemic diseases; UVB

Mesh:

Year:  2018        PMID: 30006661     DOI: 10.1007/s00105-018-4229-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  35 in total

1.  Narrowband UV-B vs medium-dose UV-A1 phototherapy in chronic atopic dermatitis.

Authors:  Franz J Legat; Angelika Hofer; Eva Brabek; Franz Quehenberger; Helmut Kerl; Peter Wolf
Journal:  Arch Dermatol       Date:  2003-02

Review 2.  Urocanic acid photochemistry and photobiology.

Authors:  T Mohammad; H Morrison; H HogenEsch
Journal:  Photochem Photobiol       Date:  1999-02       Impact factor: 3.421

Review 3.  Ultraviolet phototherapy for pruritus.

Authors:  Jennifer Rivard; Henry W Lim
Journal:  Dermatol Ther       Date:  2005 Jul-Aug       Impact factor: 2.851

Review 4.  Milestones in photoimmunology.

Authors:  Thomas Schwarz; Stefan Beissert
Journal:  J Invest Dermatol       Date:  2013-07-01       Impact factor: 8.551

5.  Phototherapy in the elderly.

Authors:  J B Powell; J E Gach
Journal:  Clin Exp Dermatol       Date:  2015-03-21       Impact factor: 3.470

Review 6.  Itch in Pregnancy Management.

Authors:  Julien Lambert
Journal:  Curr Probl Dermatol       Date:  2016-08-23

Review 7.  Advances in pathogenesis and management of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ruth Bolier; Remco van Dijk; Ronald P J Oude Elferink; Ulrich Beuers
Journal:  Dig Dis       Date:  2014-07-14       Impact factor: 2.404

Review 8.  The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD.

Authors:  M A Pathak; T B Fitzpatrick
Journal:  J Photochem Photobiol B       Date:  1992-06-30       Impact factor: 6.252

Review 9.  Folate and phototherapy: What should we inform our patients?

Authors:  Myron Zhang; Gregory Goyert; Henry W Lim
Journal:  J Am Acad Dermatol       Date:  2017-11       Impact factor: 11.527

10.  Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety.

Authors:  Surabhi Dayal; Kalpana Pathak; Priyadarshini Sahu; Vijay Kumar Jain
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

View more
  2 in total

1.  A Controlled Study of the Feasibility and Efficacy of a Cloud-Based Interactive Management Program Between Patients with Psoriasis and Physicians.

Authors:  Beibei Zhu; Yanyan Wang; Xuan Zhou; Chunyan Cao; Yan Zong; Xiaodan Zhao; Zuohong Sha; Xiaoyun Zhao; Shanhang Han
Journal:  Med Sci Monit       Date:  2019-02-04

2.  Accurate surface ultraviolet radiation forecasting for clinical applications with deep neural network.

Authors:  R Raksasat; P Sri-Iesaranusorn; J Pemcharoen; P Laiwarin; S Buntoung; S Janjai; E Boontaveeyuwat; P Asawanonda; S Sriswasdi; E Chuangsuwanich
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.